L-Dopa− and Dopamine−(R)-α-Lipoic Acid Conjugates as Multifunctional Codrugs with Antioxidant Properties

A series of multifunctional codrugs (1−4), obtained by joining L-Dopa (LD) and dopamine (DA) with (R)-α-lipoic acid (LA), was synthesized and evaluated as potential codrugs with antioxidant and iron-chelating properties. These multifunctional molecules were synthesized to overcome the pro-oxidant ef...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 49; no. 4; pp. 1486 - 1493
Main Authors Di Stefano, Antonio, Sozio, Piera, Cocco, Alessandra, Iannitelli, Antonio, Santucci, Eleonora, Costa, Mara, Pecci, Laura, Nasuti, Cinzia, Cantalamessa, Franco, Pinnen, Francesco
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society 23.02.2006
Amer Chemical Soc
Subjects
Rat
Online AccessGet full text

Cover

Loading…
More Information
Summary:A series of multifunctional codrugs (1−4), obtained by joining L-Dopa (LD) and dopamine (DA) with (R)-α-lipoic acid (LA), was synthesized and evaluated as potential codrugs with antioxidant and iron-chelating properties. These multifunctional molecules were synthesized to overcome the pro-oxidant effect associated with LD therapy. The physicochemical properties, together with the chemical and enzymatic stabilities of synthesized compounds, were evaluated in order to determine both their stability in aqueous medium and their sensitivity in undergoing enzymatic cleavage by rat and human plasma to regenerate the original drugs. The new compounds were tested for their radical scavenging activities, using a test involving the Fe (II)−H2O2-induced degradation of deoxyribose, and to evaluate peripheral markers of oxidative stress such as plasmatic activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) in the plasma. Furthermore, we showed the central effects of compounds 1 and 2 on spontaneous locomotor activity of rats in comparison with LD-treated animals. From the results obtained, compounds 1−4 appeared stable at a pH of 1.3 and in 7.4 buffered solution; in 80% human plasma they were turned into DA and LD. Codrugs 1−4 possess good lipophilicity (log P > 2 for all tested compounds). Compounds 1 and 2 seem to protect partially against the oxidative stress deriving from auto-oxidation and MAO-mediated metabolism of DA. This evidence, together with the “in vivo” dopaminergic activity and a sustained release of the parent drug in human plasma, allowed us to point out the potential advantages of using 1 and 2 rather than LD in treating pathologies such as Parkinson's disease, characterized by an evident decrease of DA concentration in the brain.
Bibliography:istex:85CF26A00C17D5EFEBD186846F722A2C98D60C3B
ark:/67375/TPS-KBXKVG8V-6
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-2623
1520-4804
DOI:10.1021/jm051145p